[Funding news] CA-based Inquis Medical Secures $40Million in Series B Round Funding

Inquis Medical, a company specializing in advanced thrombectomy systems, has raised $40 million in a Series B funding round. The round was led by Marshall Wace, with participation from existing investors including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.

As part of this funding round, Dr. Andrew D. Goldberg, a portfolio manager at Marshall Wace, has joined the company’s Board of Directors.

It plans to use the funds to complete its pivotal IDE trial, prepare for the launch of its Aventus Thrombectomy System in 2025, and continue developing its proprietary tissue-sensing technology.

Read also – [Funding news] NC-based mPATH Secures $3Million in Funding

Founded in 2020 by co-CEOs Vahid and Mojgan Saadat, Inquis Medical is a clinical-stage medical device company focused on innovations in vascular health. The company is developing thrombectomy technology that gives physicians better control, precision, and efficiency, while reducing blood loss during procedures.

The Aventus Precision Thrombectomy System™, it’s flagship product, uses unique tissue-sensing technology to provide real-time information on the tissue in contact with the device. This enhances the precision and control during procedures.

About Inquis Medical

Based in Silicon Valley, Inquis Medical focuses on improving treatments for venous thromboembolic diseases, with a goal of addressing unmet medical needs and making a lasting impact on patient care.